AbbVie exceeds Q4 earnings and sales expectations, raises outlook for key drugs, stock has positive outlook.

From Nasdaq: 2025-01-31 13:22:00

AbbVie Inc. reported Q4 2024 adjusted earnings of $2.16 per share, beating estimates and exceeding guidance. Revenues of $15.10 billion also surpassed expectations, driven by strong sales of key drugs like Rinvoq and Skyrizi. However, Humira sales declined due to loss of exclusivity in the US. ABBV issued an optimistic outlook for 2025, expecting adjusted EPS of $12.12-$12.32. Management also raised revenue forecasts for key drugs Skyrizi and Rinvoq through 2027. Shares rose over 5% in pre-market trading.

In Q4, ABBV’s immunology drugs performed well, with Rinvoq and Skyrizi sales seeing significant growth. Sales from neuroscience and oncology drugs also increased, driven by products like Vraylar and Venclexta. Aesthetics portfolio sales declined, while SG&A and R&D expenses rose. Full-year 2024 revenues were up 4.6%, but adjusted earnings decreased by 8.9% from the previous year. Management reaffirmed long-term growth expectations for key drug portfolios.

Looking beyond 2025, ABBV expects high single-digit revenue growth rates for its aesthetics and neuroscience franchises through 2029. The company’s Zacks Rank currently stands at Hold. Management also updated long-term growth outlooks for aesthetics and reaffirmed expectations for high single-digit compound annual revenue growth rates. ABBV’s stock has gained about 5% in the past year, outperforming the industry.

For more details and in-depth analysis, visit Zacks.com to stay ahead of market-making news.



Read more at Nasdaq: AbbVie Beats on Q4 Earnings & Sales, Raises Sales View for Key Drugs